CSE:PHRM - Post Discussion
Post by
AwareInvestor on Jan 19, 2021 9:25am
PharmaTher Acquires Exclusive Rights To Patented Ketamine Fo
PharmaTher has entered into an exclusive worldwide license agreement for the development and commercialization of a patented formulation of FDA-approved ketamine and betaine. The product is being viewed as a potential next-generation treatment for neurological and pain disorders as well as mental health.
Be the first to comment on this post